Enanta Pharmaceuticals Downgraded to Neutral at Zacks (ENTA)
Enanta Pharmaceuticals (NASDAQ:ENTA) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research note issued on Wednesday, Analyst Ratings Network reports. They currently have a $33.30 price target on the stock. Zacks‘ target price would indicate a potential upside of 20.78% from the company’s current price.
Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded down 1.37% on Wednesday, hitting $27.28. The stock had a trading volume of 209,319 shares. Enanta Pharmaceuticals has a 52 week low of $14.31 and a 52 week high of $38.48. The stock has a 50-day moving average of $27.48 and a 200-day moving average of $21.3. The company’s market cap is $490.0 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 25th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.00 million.
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.